J. Safra Sarasin Holding AG Increases Position in Boston Scientific Corporation $BSX

Key Points

• J. Safra Sarasin Holding AG increased its holdings in Boston Scientific Corporation by 23.2% during Q2, now owning 200,649 shares valued at $21.55 million.
• Insider transactions showed significant selling activity, with Director Yoshiaki Fujimori reducing his stake by 58.23% and EVP Joseph Michael Fitzgerald decreasing his position by 21.90%.
• Analysts have increased price targets for Boston Scientific, with Barclays raising theirs from $133 to $136 and Wells Fargo from $118 to $124, indicating a generally positive outlook for the stock.

J. Safra Sarasin Holding AG boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 23.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 200,649 shares of the medical equipment provider's stock after purchasing an additional 37,784 shares during the period. J. Safra Sarasin Holding AG's holdings in Boston Scientific were worth $21,552,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of BSX. Sound Income Strategies LLC boosted its stake in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 120 shares during the last quarter. 1248 Management LLC acquired a new stake in Boston Scientific in the first quarter valued at $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific during the 1st quarter valued at $27,000. Oliver Lagore Vanvalin Investment Group acquired a new position in Boston Scientific during the 2nd quarter worth $37,000. Finally, Activest Wealth Management grew its holdings in Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock worth $38,000 after acquiring an additional 373 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Barclays increased their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research report on Thursday. Wells Fargo & Company increased their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Raymond James Financial raised their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Finally, Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, Boston Scientific presently has an average rating of "Buy" and a consensus price target of $120.79.

Boston Scientific Price Performance

NYSE BSX opened at $96.36 on Friday. The company has a 50-day moving average price of $103.10 and a two-hundred day moving average price of $102.06. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The stock has a market cap of $142.78 billion, a price-to-earnings ratio of 57.36, a price-to-earnings-growth ratio of 2.31 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the firm posted $0.62 earnings per share. The business's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.